ECSP078003A - Inhibidores de aspartil proteasas - Google Patents

Inhibidores de aspartil proteasas

Info

Publication number
ECSP078003A
ECSP078003A EC2007008003A ECSP078003A ECSP078003A EC SP078003 A ECSP078003 A EC SP078003A EC 2007008003 A EC2007008003 A EC 2007008003A EC SP078003 A ECSP078003 A EC SP078003A EC SP078003 A ECSP078003 A EC SP078003A
Authority
EC
Ecuador
Prior art keywords
proteasas
aspartil
inhibitors
compounds
formula
Prior art date
Application number
EC2007008003A
Other languages
English (en)
Inventor
Zhaoning Zhu
Andrew Stamford
Brian Mckittrick
Johannes H Voigt
Corey Strickland
William Greenlee
Xiaoxiang Liu
Mihirbaran Mandal
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP078003A publication Critical patent/ECSP078003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se revelan compuestos de fórmula I o su estereoisómero, tautómero o sal aceptable para uso farmacéutico, donde j, k, U, W, R, R1, R2, R3, R4, R6, R7 y R7a son según se describieron anteriormente en la memoria descriptiva.Además se revela el método para inhibir la aspartil proteasa, y en particular, los métodos para tratar enfermedades cardiovasculares, enfermedades cognitivas y neurodegenerativas. Además se revelan métodos para tratar enfermedades cognitivas y neurodegenerativas utilizando los compuestos de fórmula I en combinación con un inhibidor de colinesterasa o un agonista m1 o antagonista m2 muscarínico.
EC2007008003A 2005-06-14 2007-12-12 Inhibidores de aspartil proteasas ECSP078003A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69053705P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
ECSP078003A true ECSP078003A (es) 2008-01-23

Family

ID=37114557

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007008003A ECSP078003A (es) 2005-06-14 2007-12-12 Inhibidores de aspartil proteasas

Country Status (18)

Country Link
US (1) US7868000B2 (es)
EP (1) EP1896478B1 (es)
JP (2) JP2008543849A (es)
KR (1) KR20080029965A (es)
CN (1) CN101228163A (es)
AR (1) AR054617A1 (es)
AU (1) AU2006259572A1 (es)
BR (1) BRPI0612072A2 (es)
CA (1) CA2609582A1 (es)
EC (1) ECSP078003A (es)
IL (1) IL187814A0 (es)
MX (1) MX2007016180A (es)
NO (1) NO20080187L (es)
PE (1) PE20070135A1 (es)
RU (1) RU2008100165A (es)
SG (1) SG162790A1 (es)
TW (2) TW201004961A (es)
WO (1) WO2006138264A2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
CA2610828A1 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
CN101228163A (zh) 2005-06-14 2008-07-23 先灵公司 天冬氨酰蛋白酶抑制剂
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
ATE478070T1 (de) 2005-10-27 2010-09-15 Schering Corp Heterozyklische aspartyl-proteasehemmer
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
EP2032542A2 (en) * 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
KR20090090364A (ko) * 2006-12-12 2009-08-25 쉐링 코포레이션 트리사이클릭 환 시스템을 함유하는 아스파르틸 프로테아제 억제제
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
JP2010538068A (ja) 2007-09-06 2010-12-09 シェーリング コーポレイション ガンマセクレターゼモジュレーター
EP2217604A1 (en) 2007-11-05 2010-08-18 Schering Corporation Gamma secretase modulators
US8426595B2 (en) 2007-12-11 2013-04-23 Xianhai Huang Gamma secretase modulators
CL2009000954A1 (es) * 2008-04-22 2010-12-31 Schering Corp Compuestos derivados de 2-imino-3-metil pirrolo pirimidinona,inhibidores de bace-1; composicion farmaceutica; y su uso para tratar, prevenir y/o retardar el inicio de una patologia de beta-amiloide seleccionada de enfermedad de alzheimer, enfermedad de parkinson, perdida de la memoria, sindrome de down, entre otras.
US8673900B2 (en) 2008-11-13 2014-03-18 Merck Sharp & Dohme Corp. Gamma secretase modulators
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2379566A2 (en) 2008-12-22 2011-10-26 Schering Corporation Gamma secretase modulators
CA2747744A1 (en) 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
FR2944011B1 (fr) 2009-04-03 2011-05-20 Pf Medicament Derives d'aminocyclobutane ou d'aminocyclobutene, leur procede de preparation et leur utilisation a titre de medicaments.
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US20120232108A1 (en) 2009-06-16 2012-09-13 Xianhai Huang Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
JPWO2011071109A1 (ja) * 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
JP2013542973A (ja) 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
BR112013016241A2 (pt) 2011-01-21 2016-07-12 Eisai R&D Man Co Ltd composto, e, método para fabricar um composto
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
USRE49873E1 (en) 2012-03-19 2024-03-19 Buck Institute For Research On Aging APP specific bace inhibitors (ASBIs) and uses thereof
JO3143B1 (ar) 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
JPWO2013180265A1 (ja) 2012-06-01 2016-01-21 武田薬品工業株式会社 複素環化合物
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
HUE031764T2 (en) 2012-10-26 2017-07-28 Lilly Co Eli Tetrahydropyrrolothiazine derivatives as BACE inhibitors
EP2934534B1 (en) 2012-12-21 2017-12-13 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
WO2014127042A1 (en) 2013-02-12 2014-08-21 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Ｂａｃｅ抑制劑
US9745324B2 (en) 2013-12-18 2017-08-29 Merck Sharp & Dohme Corp. Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
CN104761557B (zh) * 2015-04-08 2017-02-22 河南师范大学 六氢‑1H‑吡咯并[3,4‑d]嘧啶类化合物及其制备方法
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
WO2017139209A1 (en) * 2016-02-11 2017-08-17 Merck Sharp & Dohme Corp. C5-c6-oxacylic fused iminothiazine dioxide compounds bearing an ether linker as bace inhibitors, compositions, and their use
CN107892697B (zh) * 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
RU2020131405A (ru) 2018-02-28 2022-03-24 Джапан Тобакко Инк. Сконденсированные с насыщенным кольцом дигидропиримидиноновые или дигидротриазиноновые соединения и их применение в фармацевтике

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
US5610294A (en) 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
IT1270008B (it) * 1994-09-23 1997-04-16 Ist Superiore Sanita Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
NZ508855A (en) * 1998-06-19 2003-10-31 Vertex Pharma Sulfonamide inhibitors of HIV aspartyl protease
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
JP2004505978A (ja) 2000-08-09 2004-02-26 ベーリンガー　インゲルハイム　ファーマシューティカルズ　インコーポレイテッド （Ｒ）−３−（４−ブロモベンジル）−１−（３，５−ジクロロフェニル）−５−ヨード−３−メチル−１−Ｈ−イミダゾ［１，２−ａ］イミダゾール−２−オンの合成
ES2329975T3 (es) 2000-12-22 2009-12-03 Schering Corporation Antagonistas muscarinicos.
AU2002306734A1 (en) 2001-03-15 2002-10-03 The Johns Hopkins University Inhibitors of plasmepsins
WO2003031412A1 (en) 2001-10-10 2003-04-17 Schering Corporation Piperidine compounds as muscarinic antagonists
MXPA06001558A (es) 2003-08-08 2006-05-15 Schering Corp Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico.
EP1660443B1 (en) 2003-08-08 2009-03-04 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
US20050171112A1 (en) 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2335701B1 (en) 2003-12-15 2012-07-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
ATE423121T1 (de) 2004-06-16 2009-03-15 Wyeth Corp Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ES2332659T3 (es) 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
ATE491693T1 (de) 2004-07-22 2011-01-15 Schering Corp Substituierte amide als inhibitoren der beta- sekretase
WO2006014944A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
RS51631B (sr) 2004-08-06 2011-08-31 Janssen Pharmaceutica N.V. DERIVATI 2-AMINO-KVINAZOLINA KORISNI KAO INHIBITORI β-SEKRETAZE (BACE)
ES2403185T3 (es) 2004-08-06 2013-05-16 Janssen Pharmaceutica N.V. Nuevos derivados de 2-amino-quinazolina útiles como inhibidores de ss-secretasa (BACE)
WO2006044492A2 (en) 2004-10-14 2006-04-27 Ingenious Targeting Laboratory, Inc. Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
JP2008516946A (ja) 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ−ピリミドンおよびそれらの使用
US20090221579A1 (en) 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
CN101103034A (zh) 2005-01-14 2008-01-09 惠氏公司 抑制β-分泌酶的氨基-咪唑酮
MX2007016185A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos.
CA2610828A1 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
JP2008543844A (ja) 2005-06-14 2008-12-04 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
AR054618A1 (es) 2005-06-14 2007-07-04 Schering Corp Compuestos de azetidina y su uso como inhibidores de proteasas
CN101228163A (zh) 2005-06-14 2008-07-23 先灵公司 天冬氨酰蛋白酶抑制剂
AR054510A1 (es) 2005-06-14 2007-06-27 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas y composiciones farmaceuticas que los comprenden.
EP1896448A1 (en) 2005-06-30 2008-03-12 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
KR20080050430A (ko) 2005-09-26 2008-06-05 와이어쓰 베타-세크레타제 (ｂａｃｅ) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물
EP2612854B1 (en) 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
ATE502036T1 (de) 2005-10-25 2011-04-15 Janssen Pharmaceutica Nv Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4- düpyrimidinderivate
ATE478070T1 (de) 2005-10-27 2010-09-15 Schering Corp Heterozyklische aspartyl-proteasehemmer
EP1943246A1 (en) 2005-10-31 2008-07-16 Schering Corporation Aspartyl protease inhibitors
US20080318985A1 (en) 2005-11-15 2008-12-25 Astrazeneca Ab Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
JP2009515949A (ja) 2005-11-15 2009-04-16 アストラゼネカ・アクチエボラーグ 新規な２−アミノピリミジノン誘導体およびそれらの使用
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
CN101360737A (zh) 2005-12-19 2009-02-04 惠氏公司 2-氨基-5-哌啶咪唑酮化合物和其用于β分泌酶调节的用途
AR058381A1 (es) 2005-12-19 2008-01-30 Astrazeneca Ab Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
WO2007092839A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2007092846A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用
EP2032542A2 (en) 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
US20080051420A1 (en) 2006-06-14 2008-02-28 Astrazeneca Ab New Compounds 317
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW200817406A (en) 2006-08-17 2008-04-16 Wyeth Corp Imidazole amines as inhibitors of β-secretase
WO2008063114A1 (en) 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
JP2010512389A (ja) * 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
KR20090090364A (ko) * 2006-12-12 2009-08-25 쉐링 코포레이션 트리사이클릭 환 시스템을 함유하는 아스파르틸 프로테아제 억제제
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
CL2008000784A1 (es) 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
CL2008000791A1 (es) 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005471A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005470A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
JP5450407B2 (ja) 2007-07-06 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
WO2009092566A1 (en) 2008-01-22 2009-07-30 Boehringer Ingelheim International Gmbh Substituted amino-benzimidazoles, medicaments comprising said compound, their use and their method of manufacture
NZ586831A (en) 2008-01-28 2012-02-24 Janssen Pharmaceutica Nv 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
EP2240472B1 (en) 2008-01-29 2012-11-21 Janssen Pharmaceutica NV 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
CA2712228C (en) 2008-02-18 2013-04-16 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl amine derivatives
CL2009000954A1 (es) 2008-04-22 2010-12-31 Schering Corp Compuestos derivados de 2-imino-3-metil pirrolo pirimidinona,inhibidores de bace-1; composicion farmaceutica; y su uso para tratar, prevenir y/o retardar el inicio de una patologia de beta-amiloide seleccionada de enfermedad de alzheimer, enfermedad de parkinson, perdida de la memoria, sindrome de down, entre otras.
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
CN102105475B (zh) 2008-07-28 2014-04-09 卫材R&D管理有限公司 螺氨基二氢噻嗪衍生物
AU2009300836B2 (en) 2008-09-30 2014-02-27 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
US20100125081A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
US8394807B2 (en) 2008-11-20 2013-03-12 Purdue Research Foundation Quinazoline inhibitors of BACE 1 and methods of using

Also Published As

Publication number Publication date
PE20070135A1 (es) 2007-03-09
SG162790A1 (en) 2010-07-29
IL187814A0 (en) 2008-08-07
EP1896478A2 (en) 2008-03-12
US7868000B2 (en) 2011-01-11
WO2006138264A2 (en) 2006-12-28
RU2008100165A (ru) 2009-07-20
JP2008201784A (ja) 2008-09-04
EP1896478B1 (en) 2014-05-21
CN101228163A (zh) 2008-07-23
AU2006259572A1 (en) 2006-12-28
TW200716642A (en) 2007-05-01
KR20080029965A (ko) 2008-04-03
AR054617A1 (es) 2007-07-04
NO20080187L (no) 2008-03-14
US20070060575A1 (en) 2007-03-15
TW201004961A (en) 2010-02-01
MX2007016180A (es) 2008-03-07
WO2006138264A3 (en) 2007-03-01
TWI332005B (en) 2010-10-21
CA2609582A1 (en) 2006-12-28
BRPI0612072A2 (pt) 2010-10-19
JP2008543849A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
ECSP088959A (es) Inhibidores heterocíclicos de aspartil-proteasa
TW200716642A (en) Aspartyl protease inhibitors
TW200716567A (en) Aspartyl protease inhibitors
TW200716644A (en) Aspartyl protease inhibitors
TW200716645A (en) Macrocyclic heterocyclic aspartyl protease inhibitors
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
NZ593012A (en) Heterocyclic aspartyl protease inhibitors and their combination with cholinesterase inhibitors or muscarinic antagonists
NO20080186L (no) Heterosykliske aspartylproteaseinhibitorer, fremstilling og anvendelse derav
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
ECSP088550A (es) Nuevos compuestos que son inhibidores de erk
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
CO5680428A2 (es) Antagonistas del receptor de trombina
EA200900606A1 (ru) Новые сульфониламидные производные в качестве антагонистов брадикининовых рецепторов
EA200900605A1 (ru) Новые производные фенилсульфамоил бензамидов в качестве антагонистов брадикининовых рецепторов
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
ECSP10010303A (es) (dihidro)pirrolo[2,1-a]isoquinolinas
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer